MAPK8 and myeloid leukemia: Moreover, piplartine increased the phosphorylation of p38 and JNK in bone marrow mononuclear cells from patients with myeloid leukemias, and co-treatment with specific p38 or JNK inhibitors partially reversed piplartine-induced processes, such as ROS production and apoptotic/autophagic signaling activation (34).